News | April 22, 2011

Urgent Care Solution Shown to be More Accurate in Diabetic Patients

April 22, 2011 – The American Diabetes Association (ADA) has invited NewCardio to present the results of a key study of the company’s urgent care solution, my3KG. Results showed that the solution had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing acute myocardial infarction (AMI) in diabetic patients.

The presentation will be made at the 71st Annual ADA Scientific Sessions to be held in San Diego, Calif., June 24-28, 2011. In addition, the ADA has selected this presentation to be showcased in the Guided Audio Poster Tour, which features expert moderators that share their perspectives with attendees, highlighting novel and important developments in the field.

"We are delighted to present our study results at this important gathering of diabetes experts, and particularly pleased that the ADA program committee chose to feature our presentation in a moderated poster session,” said Ihor Gussak, M.D., Ph.D., NewCardio's chief medical officer. “Accurate and timely AMI diagnosis is a matter of great concern for diabetologists, and we believe our results show that my3KG can play a major role in solving it. The moderated poster session provides the opportunity to present our results directly to leading diabetes experts, and have one-on-one interactions that will allow us to discuss and explain the importance of our results in detail."

Diabetics with AMI represent a very large and growing patient group, and currently affect more than 10 percent of adults in the United States. Moreover, the incidence of AMI is two to four times greater in diabetics than in the general population, according to ADA and American Heart Association statistics. Accurate and timely diagnosis of AMI is notoriously difficult in diabetics, largely because the standard 12L ECG is often inaccurate, inconclusive or non-diagnostic in this patient group. To address this problem, investigators at the University of Kansas Medical Center, in collaboration with NewCardio physician-scientists, obtained detailed clinical and 12L ECG data on 155 consecutive diabetic patients with suspected AMI, and evaluated the diagnostic performance of my3KG in this patient group.

The study showed that my3KG had 42 percent greater sensitivity than expert cardiologist interpretation of 12L ECG for early detection of AMI, with equal or better specificity. Based on these important results, NewCardio believes use of my3KG in this patient group may facilitate more accurate and timely diagnosis of AMI in diabetic patients, thereby improving clinical outcomes.

The 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG. NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI. In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients.

The my3KG is not currently marketed for sale in the United States. The company intends to file an application for 510(k) approval with the U.S. Food and Drug Administration (FDA) in 2011/2012.

For more information: www.newcardio.com

Related Content

HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
iRhythm and Stanford Researchers Develop Deep Learning-Based Cardiac Arrhthymia Detection Algorithm
News | Artificial Intelligence| July 11, 2017
iRhythm Technologies Inc. announced a collaboration with the Stanford Machine Learning Group that has resulted in the...
Sponsored Content | Videos | EP Mapping and Imaging Systems| February 01, 2017
This video, provided by Medtronic, demonstrates the CardioInsight electro-anatomical mapping system.
medtronic cardioinsight electromapping system, electoanatomical mapping, noninvasive ep mapping

A screen shot of the waveforms and the the 3-D electo-mapping models created using the noninvasive CardioInsight system.

Technology | EP Mapping and Imaging Systems| February 01, 2017
February 1, 2017 — Medtronic received U.S.
Heart Test Laboratories, HTL, MyoVista ECG, common stock offering
News | ECG| January 31, 2017
Heart Test Laboratories Inc. (HTL) has successfully raised $12 million by way of a Common Stock private placement...
ecg management systems, GE Muse

The latest version of GE’s Muse ECG management system allows integration with other vendors’ ECG, stress testing and Holter monitoring systems.

Feature | ECG Management Systems| January 30, 2017 | Dave Fornell
The movement from paper electrocardiogram (ECG) review to electronic ECG management systems in the past decade has he
ECG, heartbeat, password access, electronic health records, Binghamton University SUNY study, Zhanpeng Jin
News | Electronic Medical Records (EMR)| January 26, 2017
Researchers at Binghamton University, State University of New York have devised a new way to protect personal...
Overlay Init